Friday, January 16, 2026 9:42:59 PM
froggmister,
Yep, seems a whole lot more like they were all waiting on something. A year ago last June it was announced that a newer design of a GMP Flaskworks unit would not be appropriate for fitting out the clean rooms to be built. I was not happy then but knew excessive frustration being expressed at that point would not be helpful. I expressed some disappointment and moved on.
I still believe that approval has always been tied to manufacturing, Flaskworks or similar, ever since delays seemed to start being a cover for taking care of Mr. Woodford’s comment about the “bump in the road”. His additional comments pointed to the bump being related to something expected to be part of product development. Then in 2018 Linda basically publicly begged for help with manufacturing. Now what could that bump in the road possibly be? Maybe manufacturing readiness for what MHRA, NHS, NICE, NWBO, new trials, potential partners, and others see coming is pretty important. Best wishes.
Yep, seems a whole lot more like they were all waiting on something. A year ago last June it was announced that a newer design of a GMP Flaskworks unit would not be appropriate for fitting out the clean rooms to be built. I was not happy then but knew excessive frustration being expressed at that point would not be helpful. I expressed some disappointment and moved on.
I still believe that approval has always been tied to manufacturing, Flaskworks or similar, ever since delays seemed to start being a cover for taking care of Mr. Woodford’s comment about the “bump in the road”. His additional comments pointed to the bump being related to something expected to be part of product development. Then in 2018 Linda basically publicly begged for help with manufacturing. Now what could that bump in the road possibly be? Maybe manufacturing readiness for what MHRA, NHS, NICE, NWBO, new trials, potential partners, and others see coming is pretty important. Best wishes.
Recent NWBO News
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 04/21/2026 04:15:08 AM
- Form POS AM - Post-Effective amendments for registration statement • Edgar (US Regulatory) • 04/16/2026 09:25:30 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/07/2026 04:30:50 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 03/31/2026 09:04:37 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/15/2026 10:06:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/02/2026 10:14:59 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 11/28/2025 09:43:27 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 11/25/2025 10:23:07 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/20/2025 09:26:03 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 11/19/2025 09:15:48 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/14/2025 09:44:21 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/31/2025 04:29:10 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/30/2025 08:40:05 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/24/2025 04:28:38 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/14/2025 06:22:26 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2025 09:00:38 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 07/01/2025 09:04:38 PM
